{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.9","upperLimit":"8.9","value":"8.0"},{"groupId":"OG001","lowerLimit":"7.1","upperLimit":"7.7","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)","dispersionType":"95% Confidence Interval","groups":[{"description":"Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug.","id":"OG000","title":"Panitumumab Plus BSC"},{"description":"Best supportive care defined as the best care available as judged appropriate by the investigator and according to institutional guidelines, including antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care does not include anti-neoplastic chemotherapy.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"weeks"}